MedTrace Logo

Prospective Cohort Assessing the Role of the Genotoxin Colibactin From Escherichia Coli B2 in the Genesis of NASH

NCT02390232 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 176

Last updated 2018-08-14

No results posted yet for this study

Summary

In a population of patients with Non Alcoholic Fatty Liver Disease (NAFLD), the investigators will compare the composition of the gut microbiota from patients with simple steatosis with that with steatohepatitis.

The purpose of this study is to determine if the pathogenic Escherichia Coli to the B2 group and producing the genotoxin colibactin is a factor for developing NASH.

Conditions

  • Non-alcoholic Fatty Liver Disease

Interventions

BIOLOGICAL

liver biopsy

A small needle is inserted into the liver to collect a tissue sample

BIOLOGICAL

collection of stools

collection of stools

BIOLOGICAL

blood sample

collection of blood sample

Sponsors & Collaborators

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • Maeva Guillaume, Doctor · CHU de Toulouse, hôpital Purpan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2017-11-30
Completion
2017-11-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02390232 on ClinicalTrials.gov